GSK, Pfizer resolve patent lawsuit over RSV vaccines
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Jakhar
Published On 2025-04-08 11:40 GMT | Update On 2025-04-08 11:40 GMT
Advertisement
Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware federal court.
The lawsuit alleged that Pfizer’s RSV vaccine, Abrysvo, violated GSK's patent rights in its competing RSV vaccine Arexvy.
The companies said they would dismiss the case “with prejudice,” preventing it from being refiled.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.